The Up-to-date Informations of Progesterone Supplementation for Prevention of Preterm Birth

Article information

Kosin Med J. 2013;28(1):1-6
Publication date (electronic) : 2013 January 19
doi :
Department of Obstetrics and Gynecology, College of Medicine, Inje University, Haeundae Paik Hospital, Busan, Korea
Corresponding author: Hyun Jin Cho, Department of Obstetrics and Gynecology, University of Inje College of Medicine, Haeundae Paik Hospital, Busan, Korea TEL: +82-51-797-0614 FAX: +82-51-797-2030 E-mail:
Received 2012 January 01; 2012 January 10; Accepted 2012 January 18.


Preterm birth (PTB) remains a major cause of neonatal mortality and morbidity, despite improvements in tocolytic treatment and neonatal care. Progesterone (17a-hydroxyprogesterone) produced naturally or synthetically can prevent PTB when applied vaginally and orally. Progesterone use may be a safe and cost-effective option in cases of singleton pregnancy with prior PTB, asymptomatically short cervix and arrested preterm labor.


1. WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand 1977;56:247–53.
2. Goldenberg RL. The management of preterm labor. Obstet Gynecol 2002;100:1020–37.
3. Spong CY. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol 2007;110:405–15.
4. Hall NR. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Obstet Gynecol Clin North Am 2011;38:235–46.
5. Lucovnik M, Kuon RJ, Chambliss LR, Maner WL, Shi SQ, Shi L, et al. Progestin treatment for the prevention of preterm birth. Acta Obstet Gynecol Scand 2011;90:1057–69.
6. Watari M, Watari H, DiSanto ME, Chacko S, Shi GP, Strauss JF 3rd. Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells. Am J Pathol 1999;154:1755–62.
7. Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011;38:1–9.
8. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675–80.
9. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85.
10. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267–72.
11. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. Obstet Gynecol 2006;108:492–9.
12. Saghafi N, Khadem N, Mohajeri T, Shakeri MT. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery. J Obstet Gynaecol Res 2011;37:1342–5.
13. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403–6.
14. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24.
15. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687–96.
16. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009;104:40–3.
17. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462–9.
18. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31.
19. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453. .e1-4; discussion 21.
20. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58–63.
21. Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M. Vaginal progesterone after tocolytic therapy in threatened preterm labor J Matern Fetal Neonatal Med 2011 Oct 4.
22. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–61.
23. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009;113:285–92.
24. Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011;204:54. .e1-5.
25. Rafael TJ, Mackeen AD, Berghella V. The effect of 17α -hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage. Am J Perinatol 2011;28:389–94.
26. Varma TR, Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 1982;20:13–7.
27. Kester PA. Effects of prenatally administered 17 alpha-hydroxyprogesterone caproate on adolescent males. Arch Sex Behav 1984;13:441–55.
28. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865–72.

Article information Continued